ACS chemical neuroscience molecule spotlight on saphris

Research output: Contribution to journalArticlepeer-review


On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously. Saphris (asenapine) is a multitarget atypical antipsychotic medication approved to treat adults with schizophrenia and bipolar I disorder.

Original languageEnglish (US)
Pages (from-to)263-264
Number of pages2
JournalACS Chemical Neuroscience
Issue number4
StatePublished - Apr 21 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on saphris'. Together they form a unique fingerprint.

Cite this